Cancer Research

U.S. FDA approves special protocol assessment for phase III PRECISE trial

Published in Cancer Weekly, September 20th, 2005

NeoPharm, Inc., (NEOL) announced that the U.S. Food and Drug Administration (FDA) has approved an amendment to the company's special protocol assessment (SPA), which now includes an interim efficacy analysis of data from its pivotal phase III PRECISE trial of cintredekin besudotox for the treatment of glioblastoma multiforme (GBM).

During earlier discussions, the FDA suggested that NeoPharm consider proposing an interim efficacy analysis. The SPA already included two futility analyses and a final efficacy analysis.

An interim efficacy analysis will be conducted by the independent data monitoring committee (DMC), after notification of 160 deaths to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-09-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry